Disposition of 8994 shares by Vakiener Victoria of Arrowhead Pharmaceuticals at 21.91 subject to Rule 16b-3

ARWR Stock  USD 19.65  0.85  4.52%   
Slightly above 51% of Arrowhead Pharmaceuticals' retail investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Arrowhead Pharmaceuticals suggests that some traders are interested. Arrowhead Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Arrowhead Pharmaceuticals. Many technical investors use Arrowhead Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Filed transaction by Arrowhead Pharmaceuticals Director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Read at thelincolnianonline.com
news
  
Disposition of 8994 common stock at 21.91 of Arrowhead Pharmaceuticals by Vakiener Victoria on 16th of December 2024. This event was filed by Arrowhead Pharmaceuticals with SEC on 2024-12-16. Statement of changes in beneficial ownership - SEC Form 4

Arrowhead Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Arrowhead Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Arrowhead Pharmaceuticals Fundamental Analysis

We analyze Arrowhead Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arrowhead Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arrowhead Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Revenue

Revenue Comparative Analysis

Arrowhead Pharmaceuticals is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Arrowhead Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Arrowhead Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Arrowhead Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Arrowhead Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Arrowhead Pharmaceuticals Related Equities

ASMBAssembly Biosciences   8.68   
0%
100.0%
WVEWave Life   7.68   
0%
88.0%
APLSApellis Pharmaceuticals   3.92   
0%
45.0%
AMLXAmylyx Pharmaceuticals   3.44   
0%
39.0%
PRQRProQR Therapeutics   3.40   
0%
39.0%
CTMXCytomX Therapeutics   2.91   
0%
33.0%
TERNTerns Pharmaceuticals   2.35   
0%
27.0%
BMRNBiomarin Pharmaceutical   1.16   
0%
13.0%
INCYIncyte   0.67   
0%
7.0%
DAWNDay One   0.32   
0%
3.0%
BPMCBlueprint Medicines   0.02   
1.0%
0%
IONSIonis Pharmaceuticals   0.77   
8.0%
0%
ANNXAnnexon   1.16   
13.0%
0%

Additional Tools for Arrowhead Stock Analysis

When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.